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Abstract
Purpose—The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the
efficacy and tolerability of the anti-EGFR antibody cetuximab, in persistent or recurrent
carcinoma of the cervix.
Patients and Methods—Eligible patients had cervical cancer, measurable disease, and GOG
performance status ≤2. Treatment consisted of cetuximab 400 mg/m2 initial dose followed by 250
mg/m2 weekly until disease progression or prohibitive toxicity. The primary endpoints were
progression-free survival (PFS) at 6 months and response. The study used a 2-stage group
sequential design.
Results—Thirty-eight patients were entered with 3 exclusions, leaving 35 evaluable for analysis.
Thirty-one patients (88.6%) received prior radiation as well as either 1 (n = 25, 71.4%) or 2 (n =
10) prior cytotoxic regimens. Twenty-four patients (68.6%) had a squamous cell carcinoma. Grade
3 adverse events possibly related to cetuximab included dermatologic (n = 5), GI (n = 4), anemia
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(n = 2), constitutional (n = 3), infection (n = 2), vascular (n = 2), pain (n = 2), and pulmonary,
neurological, vomiting and metabolic (n = 1 each). No clinical responses were detected. Five
patients (14.3%; two-sided 90% CI, 5.8% to 30%) survived without progression for at least 6
months. The median PFS and overall survival (OS) times were 1.97 and 6.7 months, respectively.
In this study, all patients with PFS at 6 months harbored tumors with squamous cell histology.
Conclusion—Cetuximab is well tolerated but has limited activity in this population. Cetuximab
activity may be limited to patients with squamous cell histology.
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INTRODUCTION
Cervical cancer remains the second leading cause of cancer death among women worldwide
and remains an important health problem for women especially in underserved and minority
groups in the Unites States [1]. Although cervical cancer can be cured by radical surgery or
radiotherapy with equal effectiveness, pelvic chemo-radiation represents the standard
therapy for the treatment of locally advanced disease [2]. Despite technological advances,
however, up to 35% of patients overall will develop persistent/recurrent/metastatic disease.
Platinum-based chemotherapy represents the gold standard therapy for the treatment of
cervical cancer patients who have not responded to primary therapy or have recurrent
disease no longer amenable to control with surgery and/or radiation therapy. Unfortunately,
most responses to chemotherapy are partial and of short duration, and the most effective
treatment of patients with progressive disease on platinum-based chemotherapy has yet to be
defined.
The epidermal growth factor receptor (EGFR; HER1/erbB-1) has recently been identified as
a target for cancer therapy in multiple human tumors [3–8]. On endogenous ligand binding,
EGFR activation occurs, with receptor homo- or heterodimerization and
autophosphorylation of the intracellular tyrosine kinase domain [9,10]. Subsequently, a
complex network of signal transduction pathways is induced, which plays a key role in
regulating cell proliferation, differentiation, motility, invasion, and angiogenesis [9–13].
EGFR is expressed in a variety of human malignancies and its high level of expression has
been previously correlated with poor patient prognosis and resistance to treatment in many
tumor entities including cervical carcinoma [13–18].
Cetuximab (C225) is a human/murine chimeric monoclonal antibody formed by cloning the
heavy and light chains of the murine antibody (M225) and adapting them for expression
with the constant regions of the human immunoglobulin kappa light chain and gamma 1
heavy chain [4,6,19]. Preclinical studies have demonstrated that cetuximab binds to the
EGFR with high affinity and is able to compete with EGF and TGFα binding, thereby
inhibiting subsequent receptor activation and signaling [20,21]. In addition, binding of
cetuximab to EGFR induces receptor dimerization, internalization and receptor down
regulation [22,23]. These processes may consequently lead to several effects such as cell-
cycle arrest via upregulation of cyclin-dependent kinase inhibitor p27KIP1, and potentiation
of apoptosis [24,25]. Other effects include inhibition of tumor production of VEGF leading
to reduced tumor microvessel density and inhibition of invasion and metastases by inhibiting
matrix metalloproteinases [26,27].
Clinical studies of cetuximab either alone or in combination with cytotoxic agents have
demonstrated efficacy in patients with chemotherapy-refractory head and neck or colorectal
cancer [28–32]. In patients with irinotecan-refractory advanced colorectal cancer, treatment
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with cetuximab either as a single agent or in combination with irinotecan resulted in overall
remission rates of 10.8% (95% CI, 5.7% to 18.1%) and 22.9% (95% CI, 17.5% to 29.1%),
respectively [30–31]. Similar results have been reported for patients with platinum-
refractory head and neck cancer or non–small-cell lung cancer with cetuximab in
combination with chemotherapy [32].
Cervical cancer patients with metastatic/recurrent disease not amenable to radical local
excision or regional radiation and who have progressed on platinum-based chemotherapy
have limited therapeutic options. The GOG conducted a phase II trial of single-agent
cetuximab in patients with persistent or recurrent squamous or non-squamous cervical
carcinoma. The primary endpoints of this study were the frequency of patients with tumor
responses or who survived progression-free for at least 6 months (PFS at 6 months). The
secondary objectives were to estimate the distribution of overall survival (OS), the




Eligibility criteria included patients with persistent or recurrent squamous and non-
squamous cell carcinoma of the cervix that was measurable by Response Evaluation Criteria
in Solid Tumors (RECIST); one or two prior cytotoxic regimens, not including prior
cisplatin-based chemotherapy concomitantly administered with primary pelvic radiation;
GOG performance status (PS) of 0 or 1, with PS level 2 allowed in patients having received
only one prior cytotoxic regimen; and adequate hematologic (absolute neutrophil count
≥1,500/μL and platelets ≥100,000/μL), renal (serum creatinine ≤1.5× the institutional upper
limit of normal [ULN]); hepatic (serum bilirubin ≤1.5× ULN, and both AST and alkaline
phosphatase ≤2.5× ULN) laboratory values. Histologic documentation of the original
primary tumor was required with a pathology report.
Patients with other malignancies evident within 5 years, prior non-cytotoxic therapy with
tyrosine kinase inhibitors or another antibody that targets the EGFR pathway for
management of recurrent or persistent cervical cancer, infection requiring antibiotics, active
bleeding or central nervous system (CNS) disease (craniospinal metastases, uncontrolled
seizure disorder) were ineligible. Patients were also excluded for significant cardiovascular
disease (uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure,
or uncontrolled arrhythmias within 6 months of registration) pregnancy or nursing, or major
surgical procedures within 30 days or anticipated while on study. The study received local
institutional review board approval at participating institutions and all patients provided
authorization permitting the release of personal health information and gave informed
consent according to institutional and federal guidelines before enrollment.
Treatment
Patients were treated with an initial dose of 400 mg/m2 of cetuximab followed by 250 mg/
m2 weekly until disease progression or prohibitive toxicity. Each 28 day period was
considered 1 cycle. Toxicity was monitored with history, physical examination, and
laboratory assessment before each treatment cycle, with adverse events defined and graded
according to National Cancer Institute Common Terminology Criteria version 3.0. and 4.0
Cetuximab was to be held for grade 3 non-hematologic toxicity for a maximum of 4 weeks
to allow resolution to grade 2 or less. Treatment was discontinued for any grade 4 non
hematologic toxicity or the 4th occurrence of a grade 3 acneiform rash.
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Activity of cetuximab was assessed according to RECIST (1.0 version), either by clinical
evaluation, computed tomography or magnetic resonance imaging at baseline, and before
every other cycle for the measurement of target lesions, the classification of clinical
response, and the determination of disease progression. Therapy was discontinued if there
was disease progression, unacceptable toxicity, receipt of other anticancer therapy, or
voluntary withdrawal.
Statistical Design
The primary endpoints to evaluate the activity of cetuximab were the frequency of patients
who had either a tumor response or survived progression-free for 6 months (PFS at 6
months). A 2-stage group sequential design was employed with a targeted sample size for
the first stage accrual of 19 patients but was allowed to deviate for administrative purposes
[33]. If 20 patients were accrued, the critical values to proceed to the second stage for the
number of patients with responses or PFS at 6 months were 2. The cumulative targeted
accrual for the second stage was 34 but was allowed to deviate. If 35 patients were accrued,
the critical values for the number of patients with responses or PFS at 6 months were 7
before cetuximab was deemed worthy of further investigation in a phase III trial. The null
hypothesis was determined from an examination of a historical control of a similar
population treated within GOG studies. Values of uninteresting probabilities of response and
PFS at 6 months were determined to be 10% or less. The design had a level of significance
of 10% with approximately 90% power to detect an increase in the probability of either
outcome by 20%.
The distribution of PFS and OS for patients on this study was described using Kaplan-Meier
plots and median estimates. Prognostic factors were evaluated with Cox proportional
hazards models using end points for PFS and OS [34]. The factors assessed included
performance status of 0 or worse along with squamous versus non-squamous histology.
Formal inference could not be done on race since there were only 5 African-Americans on
study. These analyses are considered exploratory.
RESULTS
Patient characteristics
From June 2007 through July 2009, 38 patients were enrolled, of whom 3 were excluded (1
for inappropriate prior therapy, 1 because required tests were not performed, and 1 for no
documentation of treatment with cetuximab). Thus, the study sample consisted of 35
patients; 26 patients (74.3%) were Caucasian, 5 patients (14.3%) were African-American, 2
patients (5.7%) were Asian and 2 (5.7%) were Hispanic. Patient characteristics of the study
group are listed in Table 1.
A total of 103 cycles of cetuximab were administered, with 18 patients receiving 2 cycles of
treatment (51.4%). As of July 2010, all patients have discontinued therapy, 31 patients were
taken off of study for disease progression, 3 discontinued therapy for toxicity as permitted
by protocol, and one was taken off study protocol for other reasons (i.e., physician decision).
Twenty-six patients died of disease progression. Seven patients (20%) are alive; one patient
died from treatment and disease and another died from neither treatment nor disease.
Activity of cetuximab
The first stage of the study acquired 20 eligible and evaluable patients. None of these
patients had tumor responses but 4 were PFS at 6 months, which was sufficient to open the
study to a second stage. The activity of cetuximab was analyzed in a cumulative number of
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35 patients. No clinical responses were detected (Table 2). Five patients (14.3%; two-sided
90% CI, 5.8% to 30%) were PFS at 6 months. The median PFS and OS times were 1.97 and
6.7 months, respectively. The graph of the Kaplan-Meier estimates of PFS and OS for the
sample is shown in Figure 1. All 5 patients with PFS at 6 months harbored tumors with
squamous cell histology, which comprised 69% of the sample. In an exploratory subgroup
analysis of these patients, the point estimates for the probability of being progression-free at
6 months was higher among the squamous patients than the whole sample (21% versus 14%,
Figure 2). The 95% CI for the odds ratio was 0.59 to infinity.
Adverse Events
As shown in Table 3, safety of cetuximab in all 35 patients was analyzed descriptively;
events listed had been reported as at least possibly related to study drug. There were no
grade 4 events. One patient was listed by the GOG Data Safety and Monitoring Board as
having died from both treatment and disease (bowel perforation) but the institution did not
agree. Grade 3 adverse events at least possibly related to cetuximab included dermatologic
events (n = 5), GI (n = 4), anemia (n = 2), constitutional symptoms (n = 3), infection (n = 2),
vascular events (n = 2), pain (n = 2), and pulmonary, neurological, vomiting and metabolic
events (n = 1 each).
Exploratory Analysis of Patient Characteristics and PFS and OS During Treatment With
Cetuximab
Results of the exploratory analyses are reported in Table 4. Performance status may be a
prognostic factor associated with OS and possibly PFS. The low number of African
Americans included in our study (i.e., a total of 5 patients) prevented the determination of
the confidence interval between races. The approximate 95% confidence interval for
squamous cell type versus all other cell types ranged from 0.33 – 1.52 for PFS and from
0.33 – 1,57 for OS, respectively, indicating uncertainty of the activity of single agent
cetuximab within this subgroup.
DISCUSSION
The management of cervical cancer no longer amenable to control with surgery or radiation
therapy has only minimally improved with the advent of modern chemotherapy. The median
survival rate for these patients when treated with current systemic cisplatin combination
regimens is only 9 to 10 months [35,36]. Thus, the development of innovative, effective
therapies against advanced/recurrent/metastatic cervical cancer refractory to standard
salvage treatment remains a high priority.
One class of agents with potential activity in this group of patients is represented by
cetuximab, a human/murine chimeric monoclonal antibody targeting the epidermal growth
factor receptor. Phase I/II studies of cetuximab in locoregionally advanced squamous-cell
cancer of the head and neck (SCCHN) showed promising activity in combination with
radiotherapy [37,38]. Importantly, in patients with metastatic and recurrent SCCHN who
have not responded to platinum-based therapy, cetuximab as a single agent or in
combination with chemotherapy has been shown to induce responses. In the study by
Baselga et al., patients with metastatic and recurrent SCCHN who had progressed following
a platinum-containing regimen were re-challenged with the same regimen with the addition
of cetuximab [39]. In 96 evaluable patients, the proportion responding was 14.6% and
39.6% had stable disease. Vermorken et al. evaluated cetuximab monotherapy in 103
patients with metastatic and recurrent SCCHN who had progressed following a platinum-
containing regimen [40]. Treatment with cetuximab produced a response rate of 13% and a
disease control rate (complete response/partial response/stable disease) of 46%. The current
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study was designed by the GOG to test the therapeutic benefit of single-agent cetuximab in
the setting of treatment failure with 1 or 2 prior regimens for metastatic cervical cancer with
squamous and non-squamous histology. In this group of heavily pretreated patients
cetuximab showed limited activity, with a response rate of 0% and 14.3% of patients
remaining without progression after 6 months on protocol. Because the required number of
patients with either responses or PFS at 6 months to declare the regimen interesting was 7
and 7 out of 35 patients (20.0%), respectively, the study was negative for the entire
population. A median OS of 6.7 months was found in the current study. It is worth noting,
however, that 5 out of 24 of the study patients (21%) who survived progression free for at
least 6 months on cetuximab therapy harbored tumors with squamous cell histology. In
contrast, no patient survived progression free for at least 6 months in the group of patients
treated with cetuximab harboring adenosquamous or adenocarcinoma of the cervix (0 out of
11 patients). Consistent with these results, the point estimates for the probability of being
PFS at 6 months when receiving cetuximab therapy was higher among the patients harboring
squamous tumors than the whole sample (21% versus 14%). Thus, although the overall level
of activity in the current report does not justify a phase III trial of cetuximab in heavily
pretreated advanced and recurrent cervical cancer patients, current data cannot rule out
potential activity of cetuximab in patients harboring cervical tumors with squamous cell
histology.
The safety profile of cetuximab has been extensively studied in previous reports [37–41].
The present study did not identify any new toxicities or an increased frequency of currently
reported toxicities of cetuximab in cervical cancer patients with persistent or recurrent
disease. Most of the Grade 3 adverse events reported in the study were related to
dermatologic toxicity.
In the current trial, patients were not prescreened or preselected on the basis of EGFR
expression. It is worth noting, however, that the relation between EGFR protein expression
and response to EGFR-target therapies is questionable, as colorectal cancer patients without
detectable EGFR protein over-expression may respond to treatment with cetuximab [41].
Moreover, multiple previous studies have shown that EGFR is overexpressed in a large
number of cervical cancers, and that it is significantly more expressed in squamous cell
carcinoma than in adenocarcinoma and the upregulation is correlated with poor prognosis
[42]. Of interest, multiple biomarkers have been found to predict response to treatment with
EGFR inhibitors in other human malignancies. For example, in colorectal cancer and non–
small cell lung cancer, KRAS mutations are associated with resistance to EGFR inhibitors,
whereas specific EGFR mutations and high copy numbers of the EGFR gene predict a better
response in non–small cell lung cancer [43–45]. In cervical cancer, however, neither EGFR
mutations nor EGFR gene amplification and only a few (0–8%) KRAS mutations have been
reported [46–51].
Although multiple mechanisms of action have been attributed to cetuximab including
inhibition of tumor proliferation, angiogenesis and metastasis, induction of apoptosis, and/or
promotion of cell cycle arrest, strong experimental evidence suggests that engagement of Fc
receptors on effector cells (i.e., mainly natural killer (NK) cells) represents the dominant
component of the in vivo activity of most antibodies against tumors [52–55]. The efficacy of
the anti-EGFR antibody (M225) when used as an F(ab)2 in blocking the growth of tumors in
vivo has been previously demonstrated to be only 50% of the activity shown by the intact
antibody when it is able to engage the Fc receptors on NK cells [53]. These findings suggest
that host factors related to a low number and/or lack of killing activity of effector cells (i.e.,
NK cells), as previously reported by multiple groups studying the immune-competence of
cervical cancer patients heavily pretreated with radiation and chemotherapy, may present a
major barrier to the successful clinical development of therapeutic biologic reagents (i.e.,
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IgG1 mAb such as cetuximab) in end-stage cervical cancer patients [56–58]. Prospective
evaluation of the immune-competence of such patients therefore seems to be warranted in
future studies.
In conclusion, our study indicates that cetuximab has limited activity in patients with
persistent or recurrent cervical cancer that has progressed after chemo-radiation and
palliative chemotherapy. Cetuximab seems to be well tolerated in this patient population and
its activity may be greater in patients with squamous cell histology.
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• The GOG evaluated the efficacy and tolerability of Cetuximab in cervical cancer
• Cetuximab is well tolerated but has limited activity in persistent/recurrent
disease
• Cetuximab activity may be limited to cervical cancer with squamous cell
histology
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Kaplan-Meier estimates of PFS and OS for the entire study population.
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Kaplan-Meier estimates of PFS and OS for the study population of patients harboring
squamous versus non-squamous cervical cancer.
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Table 1
Patient Characteristics
Characteristic Category No. of % of




Race Asian 2 5.7
African American 5 14.3
Hispanic 2 5.7
White 26 74.3
Performance Status 0 24 68.6
1 9 25.7
2 2 5.7
Cell Type Adenocarcinoma, Unsp. 4 11.4
Mixed Epithelial Carcinoma 1 2.9
Adenosquamous 6 17.1
Squamous Cell Carcinoma 24 68.6
Grade 1: Well differentiated 6 17.1
2: Moderately differentiated 16 45.7
3: Poorly differentiated 12 34.3
Unknown 1 2.9
Prior Chemotherapy 1 Prior Regimen 25 71.4
2 Prior Regimens 10 28.6
Prior Radiation No 4 11.4
Yes 31 88.6
Prior Surgery No 19 54.3
Yes 16 45.7
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Table 2
Patient Response and Progression-Free Survival Status
Characteristic Category No. % of
Response Stable disease 11 31.4
Increase disease 23 65.7
Indeterminate 1 2.9
PFS > 6 Months No 30 85.7
Yes 5 14.3





Alive Without progression 1 2.9
With progression 6 17.1
Dead From disease 26 74.3
From Rx and disease 1 2.9
From neither Rx nor 1 2.9
The observed proportion responding was 0.0%. The approximate 90% confidence interval for the true response rate is 0 – 6.4%. The observed
proportion of patients surviving progression free for at least 6 months was 14.3%. The approximate 2-sided 90% CI for the probability of being
PFS at 6 months is 5.8 – 30.0%. The approximate 1-sided 90% CI for the probability of being PFS at 6 months is 0.0– 26.8%. The required number
of patients with either responses or PFS at 6 months to declare the regimen interesting was 7 and 7 out of 35 patients (20.0%), respectively.
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Table 4
Cox Proportional Hazard Ratio Estimates for Various Prognostic Factors
Progression-Free Survival
Prognostic Factor Hazard Ratio 95% Confidence Interval
Performance Status1 1.77 0.82 – 3.82
Race2 0.69 N/A4
Squamous Histology3 0.72 0.33 – 1.52
Overall Survival
Performance Status1 2.42 1.01 – 5.78
Race2 1.02 N/A4
Squamous Histology3 0.72 0.33 – 1.57
1
Performance Status of 1 or 2 versus 0
2
African American versus all other races
3
Squamous Cell Type versus all other cell types
4
The confidence interval could not be determined because there were only 5 African Americans.
Gynecol Oncol. Author manuscript; available in PMC 2012 September 1.
